When Atopic Dermatitis is Difficult to Control
Price: FREE for members and non-members
Session recorded on January 23, 2020
Speaker: William E. Berger, MD, FACAAI
Viewers can earn credit by completing the post test questions.
Atopic dermatitis is the most common form of eczema affecting 18 million adults and 9.6 million children under 18 years of age in the United States. Many patients are not being treated adequately and this is having a severe impact on their quality of life.
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
There is no commercial support for this activity.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Physicians
Upon viewing the video recording, learners should be able to:
1. Identify the most common triggers of atopic dermatitis (AD) symptoms
2. Utilize appropriate strategies for patients with severe AD
3. Improve control of AD and implement new treatment regimens
All identified conflicts of interest have been resolved.
Michael Blaiss, MD, Planner
Disclosures: Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
William E. Berger, MD, Speaker
Disclosures: Speaker/honorarium: Astra Zeneca, Boehringer Ingelheim, Optinose
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance